Arab Finance: GlaxoSmithKline (GSK – Egypt) (BIOC) reported a 934.9% year-on-year (YoY) surge in standalone net profit after tax during the first nine months of 2022, according to the financial statement filed to the Egyptian Exchange (EGX) on November 15th.

The company’s standalone net profit soared to EGP 929.74 million in January-September from EGP 89.839 million in the same period a year earlier.

GSK Egypt, a member of the British pharmaceutical company Glaxo Group, is an Egypt-based company engaged in the manufacturing, packaging, marketing, selling, and distribution of pharmaceutical products.